Stockreport

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome [Yahoo! Finance]

Kyverna Therapeutics, Inc.  (KYTX) 
PDF Miv-cel achieved statistically significant clinical benefit across all primary and secondary endpoints, reversing disability and eliminating immunotherapies after a sin [Read more]